Renalytix AI (RNLX)
(Real Time Quote from BATS)
$0.30 USD
0.00 (0.44%)
Updated Jul 23, 2024 10:34 AM ET
2-Buy of 5 2
F Value B Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RNLX 0.30 0.00(0.44%)
Will RNLX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RNLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RNLX
New Strong Buy Stocks for October 26th
What Makes Renalytix AI PLC Sponsored ADR (RNLX) a New Strong Buy Stock
RNLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for October 12th
Renalytix AI PLC Sponsored ADR (RNLX) Loses -44.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Momentive (MNTV) Surges 10.1%: Is This an Indication of Further Gains?
Other News for RNLX
Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US
Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination
Renalytix AI’s KidneyIntelX Gains Medicare Coverage Approval
Medicare Issues Final Coverage Determination for kidneyintelX.dkd
Renalytix announces Medicare issued coverage determination for kidneyintelX.dkd